The Medical Advisor

Abstract   Pancreatic cancer remains one of the most lethal malignancies, often diagnosed at advanced stages with limited treatment options. Recent studies and anecdotal reports suggest that repurposed drugs and alternative therapies may offer new hope for improving patient outcomes. This review examines emerging evidence on ivermectin, fenbendazole, high-dose vitamin C, and hydroxychloroquine as potential adjunct therapeutic agents for pancreatic cancer. While preliminary findings are promising, further clinical trials are necessary to establish their efficacy and safety. Keywords: Pancreatic cancer, ivermectin, fenbendazole, vitamin D, hydroxychloroquine, repurposed drugs, chemotherapy, high-dose vitamin C, immunotherapy Pancreatic Cancer Awareness 1. Introduction   Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. Appr...

Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years. While some chemotherapies are initially effective, pancreatic tumors often become resistant to them. The disease has also proven difficult to treat with newer approaches such as immunotherapy. Over 30 clinical studies are still evaluating the activity of both Chloroquine and HydroxyChloroQuine in different cancer types and in combination with various standard treatments. Dr Steve Bigelsen  Steve Bigelsen, MD is a physician specializing in Allergy and Asthma, who in July 2016 was  diagnosed with pancreatic adenocarcinoma . He had tumors in the head and the tail with scattered peritoneal metastases and a CA19-9 of 11,575 U/ml. Working with physicians from Weill-Cornell and Johns Hopkins, he began treatment with gemcitabine and capecitabine, plus IV paricalcitol (an analog of  Vitamin D ) and ...